Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The company said it reached a US$5.5 billion agreement aimed at resolving tens of thousands of lawsuits tied to allegations that talc-containing baby powder caused health harms. Terms were not fully detailed in the report.
THE APEX TIMES
THE APEX TIMES
In remarks tied to its latest earnings discussion, Moderna indicated it will hold to its 2026 growth target as it adjusts spending plans, while pushing forward programs across flu, oncology, and rare diseases toward upcoming milestone events.
THE APEX TIMES
The biotech said it has launched a first-in-human study in Canada for an investigational mRNA vaccine targeting Bundibugyo ebolavirus, a strain of Ebola that has no approved vaccine in the segment the company is pursuing.
THE APEX TIMES
The new report, distributed via a GlobeNewswire announcement syndicated on Yahoo Finance, examines the global influenza vaccine market and includes company profiles of Pfizer, GSK, Sanofi and Moderna.
THE APEX TIMES
Despite reporting higher second-quarter sales and profit, CVS Health drew a sharp selloff in early August after lifting its 2026 outlook and expanding its relationship with Eli Lilly around GLP-1 medicines.
THE APEX TIMES
Moderna said the U.S. Food and Drug Administration approved its flu vaccine candidate mFLUSIVA. The approval adds a new regulatory milestone, though the near-term financial implications depend on pricing, uptake, and how quickly the product scales through the season.
THE APEX TIMES
A Wall Street fair-value target for CVS Health has risen slightly, from about $111.92 to $114.88, reflecting a more constructive tone from analysts according to a report published by Yahoo Finance.
THE APEX TIMES
The US Food and Drug Administration’s approval of mFLUSIVA, Moderna’s mRNA-based flu vaccine for adults 50 and older, has reignited attention on the product’s commercial outlook and whether its pricing can support sustained growth for the company.
THE APEX TIMES
Shares fell after the U.S. Food and Drug Administration approved Moderna’s mRNA-based flu vaccine, branded mFlusiva, leaving investors to wonder whether the company’s development and commercialization plans will “restart” after the regulatory milestone.
